| ID Source | ID |
|---|---|
| PubMed CID | 6450313 |
| MeSH ID | M0094505 |
| Synonym |
|---|
| 2-(4-(3-(2-chloro-9h-thioxanthen-9-ylidene)propyl)piperazinyl) decanoate |
| clopenthixol decanoate (ester) |
| clopenthixol decanoate |
| 55501-05-8 |
| unii-2hfx55af4y |
| einecs 259-675-7 |
| 2hfx55af4y , |
| ciatyl depot |
| zuclopenthixole decanoate |
| clopentixol decanoate |
| sordinol depot |
| decanoic acid, 2-(4-((3e)-3-(2-chloro-9h-thioxanthen-9-ylidene)propyl)-1-piperazinyl)ethyl ester |
| (e)-clopenthixol decanoate |
| clopenthixol decanoate, trans |
| WBS0PLG8GD |
| trans-clopenthixol decanoate |
| Q27292551 |
| transclopenthixol decanoate |
| DTXSID80897157 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events related to movement disorders were reported in 3%." | ( Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) | 0.32 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic profiles of the three injectable zuclopenthixol preparations are very different." | ( Pharmacokinetics of three different injectable zuclopenthixol preparations. Aaes-Jørgensen, T, 1989) | 0.28 |
| " The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i." | ( Clinical pharmacokinetics of the depot antipsychotics. Ereshefsky, L; Jann, MW; Saklad, SR, ) | 0.13 |
| " Moreover pharmacokinetic data increasingly have been clinically applied." | ( Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Knudsen, P, 1985) | 0.27 |
| "Precise pharmacokinetic data of long-acting neuroleptics: apparent half life (T 1/2), time of peak plasma concentration (Tmax), bioavailability, has been a major contribution to determine optimal dosage of the drug." | ( [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. Levron, JC; Ropert, R, ) | 0.13 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The absorption rate constant is slower than the elimination rate constant and therefore, the depot antipsychotics exhibit 'flip-flop' kinetics where the time to steady-state is a function of the absorption rate, and the concentration at steady-state is a function of the elimination rate." | ( Clinical pharmacokinetics of the depot antipsychotics. Ereshefsky, L; Jann, MW; Saklad, SR, ) | 0.13 |
| " Optimal dose has been determined from the bioavailability of the oral formulation and the interval between two injections, it averages 15, 20 times the oral daily dose for haloperidol decanoate." | ( [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. Levron, JC; Ropert, R, ) | 0.13 |
One hundred and sixteen mentally handicapped patients with behavioural disorders were studied in a double-blind clinical comparison. Maximum concentrations appeared at 1 week after administration of cis(Z)-clopenthixol decanoate, whereas the highest concentrations after fluphenazineDecanoate were seen at the end of the 3-week dosage interval.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients were treated until the acute episode was considered terminated by the clinician and, although dosage could be adjusted to allow optimum clinical response, the majority received 25 mg zuclopenthixol dihydrochloride 3-times daily throughout the trial period." | ( A clinical assessment of zuclopenthixol dihydrochloride (Clopixol tablets) in the treatment of psychotic illness. Clayton, AR; Mann, BS; Moslehuddin, KS; Owen, RT; Rohatgi, KK; Sud, P; Vaddadi, KS, 1985) | 0.27 |
| "Precise pharmacokinetic data of long-acting neuroleptics: apparent half life (T 1/2), time of peak plasma concentration (Tmax), bioavailability, has been a major contribution to determine optimal dosage of the drug." | ( [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. Levron, JC; Ropert, R, ) | 0.13 |
| "Seventeen outpatients were treated with depot neuroleptics, zuclopenthixol decanoate in Viscoleo or fluphenazine decanoate in sesame oil, with dosage intervals of 3 weeks." | ( Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Ba, B; Durand, A; Gouezo, F; Hou, N; Jørgensen, A; Viala, A, 1988) | 0.77 |
| "One hundred and sixteen mentally handicapped patients with behavioural disorders were studied in a double-blind clinical comparison of zuclopenthixol decanoate injection (mean dosage 123 mg/week) and placebo." | ( Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients. Izmeth, MG; Khan, SY; Kumarajeewa, DI; Shivanathan, S; Veall, RM; Wiley, YV, 1988) | 1.2 |
| " Maximum concentrations appeared at 1 week after administration of cis(Z)-clopenthixol decanoate, whereas the highest concentrations after fluphenazine decanoate were seen at the end of the 3-week dosage interval." | ( Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Ba, B; Berda, C; D'Agostino, N; Dufour, H; Durand, A; Hou, N; Jørgensen, A; Viala, A, 1984) | 0.5 |
| ") was given intramuscularly to nine schizophrenic patients with dosage intervals of 1 or 2 weeks." | ( Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo. Aaes-Jørgensen, T; Danneskiold-Samsøe, P; Jørgensen, A; Kirk, L; Petersen, E, 1983) | 0.48 |
| " The aim of this review is to represent the chemistry, pharmacology, pharmacokinetics, dosage and efficacy of this drug." | ( [cis(Z)-Clopenthixol decanoate--a new depot neuroleptic]. Sieberns, S; Spechtmeyer, H, 1982) | 0.7 |
| "0 and was independent of the dosage given." | ( Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Larsen, NE; Olesen, OV; Poulsen, JH, 1994) | 0.52 |
| " These patients require close monitoring for adverse effects with adjustment of dosing to ensure the optimal balance of risk versus benefit while the patient is acutely psychotic." | ( Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report. Harvey, R; Kekulawala, S; Kent, M; Mostafa, S; Tucker, MG, 2016) | 0.43 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 25 (64.10) | 18.7374 |
| 1990's | 3 (7.69) | 18.2507 |
| 2000's | 6 (15.38) | 29.6817 |
| 2010's | 5 (12.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (22.73%) | 5.53% |
| Reviews | 2 (4.55%) | 6.00% |
| Case Studies | 9 (20.45%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (52.27%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||